Table 3 Impact of allogeneic unrelated transplant on overall survival in the whole cohort of 326 patients and by diagnosis (multivariable Cox proportional hazard model)

Multivariable models	HR	CI (95%)	P-value
Total (N=326, deaths=244)
Gender (F vs M)	0.85	(0.65–1.10)	0.209
Age at activation (⩾50 vs <50 years)	1.21	(0.92–1.58)	0.175
Disease risk status (high vs standard)	0.91	(0.69–1.21)	0.526
Unrelated transplant^a	0.89	(0.67–1.20)	0.445
AML/ALL (N=67, deaths=51)
Gender (F vs M)	0.79	(0.42–1.51)	0.478
Age at activation (60–65 vs 55–60 years)	1.57	(0.37–6.72)	0.540
Unrelated transplant^a	0.60	(0.34–0.99)	0.049
CML–MDS–MMF (N=41, deaths=30)
Gender (F vs M)	0.79	(0.36–1.77)	0.569
Age at activation (60–65 vs 55–60 years)	1.92	(0.42–8.74)	0.401
Unrelated transplant^a	1.21	(0.49–3.00)	0.684
HD (N=104, deaths=77)
Gender (F vs M)	0.99	(0.62–1.57)	0.958
Age at activation (⩾50 vs <50 years)	0.80	(0.29–2.24)	0.677
Previous autologous transplant (yes vs no)	0.92	(0.50–1.70)	0.789
Unrelated transplant^a	0.67	(0.40–1.13)	0.136
NHL–MF/SS (N=80, deaths=59)
Gender (F vs M)	0.93	(0.54–1.75)	0.926
Age at activation (⩾50 vs <50 years)	0.97	(0.57–1.67)	0.915
Previous autologous transplant (yes vs no)	1.07	(0.60–1.93)	0.813
Unrelated transplant^a	0.47	(0.27–0.82)	0.008
CLL (N=34, deaths=27)
Gender (F vs M)	0.75	(0.32–1.77)	0.510
Age at activation (⩾50 vs <50 years)	1.21	(0.53–2.77)	0.653
Previous autologous transplant (yes vs no)	1.41	(0.62–3.20)	0.412
Unrelated transplant^a	1.58	(0.57–4.37)	0.382

Abbreviations: ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; CI, confidence interval; CLL, chronic lymphoid leukemia; CML, chronic myeloid leukemia; F, female; HD, Hodgkin's disease; HR, hazard ratio; M, male; MDS, myelodysplastic Syndrome; MF, mycosis fungoides; MMF, myelofibrosis; NHL, non-Hodgkin's lymphoma; SS, Sezary’s syndrome.
^aTime-dependent covariate. The significant variables are underlined.

Search